menu
    • menu
    [{"orgOrder":0,"company":"Affibody","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Affibody","amount2":0.20999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20999999999999999,"dosageForm":"Oral","sponsorNew":"Affibody \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Affibody \/ Chiesi Group"},{"orgOrder":0,"company":"Affibody","sponsor":"Acelyrin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Affibody","highestDevelopmentStatusID":"9","companyTruncated":"Affibody \/ Affibody"},{"orgOrder":0,"company":"Affibody","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inapplicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inapplicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Affibody","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Affibody"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ABY-035","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affibody \/ Affibody","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Affibody"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Affibody \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inmagene Biopharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Affibody

    Menu

    Affibody

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Discovery

                            Sponsor : Chiesi Group

                            Deal Size : $214.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Affibody And Chiesi Group Collaborate To Develop And Commercialize Innovative Treatments For Respiratory Disea...

                            Details : Under the terms of the collaboration, Affibody and Chiesi Group will collaborate closely to progress up to three programs based on Affibody® molecules against undisclosed targets for respiratory diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Discovery

                            Sponsor : Chiesi Group

                            Deal Size : $214.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Acelyrin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibe...

                            Details : IMG-020 (Izokibep), a unique, antibody mimetic, interleukin-17A (IL-17A) inhibitor was well-tolerated in the study, having a favorable safety profile consistent with that previously observed for izokibep and the IL-17A inhibitor therapeutic class.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 06, 2022

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Acelyrin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Inmagene Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inmagene and Affibody Announce IND Clearance for Izokibep (IMG-020) For the Treatment of Ankylosing Spondyliti...

                            Details : IMG-020, Inmagene's most advanced drug candidate, is in global clinical trials for multiple indications. The trial will evaluate the efficacy, safety and tolerability of three different dosage regimens of izokibep as compared to placebo.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 02, 2021

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Inmagene Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABY-035

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Inmagene Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 12, 2021

                            Lead Product(s) : ABY-035

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Inmagene Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Affibody Announces Initiation of Confirmatory Phase 2 Trial of ABY-035 in Psoriatic Arthritis Patients

                            Details : The study is a multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial in patients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 11, 2020

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis

                            Details : The Phase 2 AFFIRM-35 trial in patients with moderate-to-severe psoriasis has shown excellent and sustained clinical response in patients. Based on these encouraging clinical results, clinical development program of ABY-035 has been expanded to include f...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 16, 2020

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inmagene Biopharmaceuticals

                            Deal Size : $225.5 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Affibody and Inmagene Announce Strategic Partnership to Develop ABY-035

                            Details : The parties will develop and commercialize ABY-035 for multiple auto-immune diseases. Inmagene will Commercialize ABY-035 in mainland China, Hong Kong, Taiwan, and Macau, and South Korea, and will run developmental activities in the Asia Pacific region.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $10.0 million

                            May 15, 2020

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inmagene Biopharmaceuticals

                            Deal Size : $225.5 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABY-035

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : TFS Trial Form Support

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 19, 2018

                            Lead Product(s) : ABY-035

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : TFS Trial Form Support

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABY-035

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 09, 2018

                            Lead Product(s) : ABY-035

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed

                            Affibody

                            Sweden arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABY-039

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 19, 2018

                            Lead Product(s) : ABY-039

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth